NEWS

WIRES

OTHER

Sigma Medical Signs Joint Venture With Stason Pharmaceuticals to Create Line of Generic Drugs

Company Seeks Approval to Manufacture and Market Line of Affordable Generic Drugs for Chronic Conditions by 2006

Sigma Medical , a division of Sigma Global Corporation today announced it has signed a joint venture agreement with Stason Pharmaceuticals, a leading contract pharmaceutical manufacturer, to create its own line of generic pharmaceuticals, according to Sigma Medical Chairman and Chief Executive Officer, Bryan Chance.

Over the next 18-24 months, Sigma plans to file for governmental approval to manufacture generic equivalents of 8-10 of the nation's most popular pharmaceuticals used to maintain health in the most common chronic disease conditions. The partnership will also open up the Pacific Rim as a distribution channel for Sigma.

Generic pharmaceuticals represent an increasing proportion of the medications dispensed in the United States. Furthermore, generic drugs account for 51% of all prescriptions dispensed in the United States, with more than $38 billion in 2003 sales. Analysts are projecting annual sales for generic products will be in excess of $22 billion by 2005.

"The partnership with Stason Pharmaceuticals is a significant step in achieving our long-term goal of being a leading supplier of affordable, easy to maintain, chronic care health solutions," said Chance. "The ability to manufacture and market our own line of high-quality, low-cost generic alternatives to popular chronic-care medications is a key milestone in achieving our goals. Stason is a global provider, and we are pleased to have them as a partner."

Located in Irvine, California, Stason Pharmaceuticals www.stason.com)"> is a leading developer and manufacturer of state-of-the-art pharmaceutical products. Stason is an affiliate of Standard Chemical and Pharmaceuticals, a leading Taiwan-based biotech and pharmaceutical company.

"We look forward to setting this partnership with Sigma Medical in motion," said Harry Fan, Chief Executive Officer of Stason. "This is an ideal partnership, where the two companies combine their strengths and streamline product development and commercialization of important drugs, not only in North America but in the Pacific Rim through our distribution network."

About Sigma Global Corporation and Sigma Medical

Sigma Global Corporation is dedicated to providing innovative direct-to-consumer medical products and services, including a suite of integrated programs that help improve the process of long-term health maintenance for seniors and those suffering from chronic disease. Sigma Medical operates a fully licensed pharmacy and distribution center that serves healthcare facilities, physicians and patients throughout North America and Puerto Rico. For more information on Sigma Medical, go to the website .

About Stason Pharmaceuticals

Stason Pharmaceuticals, established in 1994, is a cGMP solution provider, specializing in product research, clinical trial materials, drug delivery systems and pharmaceutical manufacturing. Headquartered in Irvine Spectrum, a high-tech industrial park in the City of Irvine, in Southern California, the company also provides contract services and has successfully developed formulations and manufactured clinical trial supplies for drug development companies. Stason's 37,000 square-foot facility includes a 10,000 sq. ft. GMP cleanroom area and an 8,000 sq. ft. laboratory, with the remaining space for administrative and warehousing functions. For more information on Stason, go to the website www.stason.com.

Statements that are not historical facts are forward-looking statements. The Company, through its management, makes forward-looking public statements concerning its expected future operations, performance and other developments. Such forward-looking statements are necessarily estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. It is impossible to identify all such factors, factors that could cause actual results to differ materially from those estimated by the Company. They include, but are not limited to, government regulation, managing and maintaining growth, and the effect of adverse publicity, litigation, competition and other factors that may be identified from time to time in the Company's public announcements.